Troglitazone

Troglitazone is an antidiabetic and anti-inflammatory drug, and a member of the drug class of the thiazolidinediones. It was prescribed for people with diabetes mellitus type 2.[1] It was patented in 1983 and approved for medical use in 1997.[2] It was subsequently withdrawn. Contents 1 Mechanism of action 2 History 3 Mechanisms of hepatotoxicity 4 Lawsuits 5 References 6 External links Mechanism of action Troglitazone, like the other thiazolidinedione... [wikipedia]